Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C7H10N3O6S.Na |
| Molecular Weight | 287.226 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC(=O)[C@@H]1CC[C@@H]2C[N@]1C(=O)N2OS([O-])(=O)=O
InChI
InChIKey=RTCIKUMODPANKX-JBUOLDKXSA-M
InChI=1S/C7H11N3O6S.Na/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15;/h4-5H,1-3H2,(H2,8,11)(H,13,14,15);/q;+1/p-1/t4-,5+;/m1./s1
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C7H10N3O6S |
| Molecular Weight | 264.236 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, covalent, slowly reversible β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. The combination of ceftazidime with avibactam exhibited broad-spectrum activity against Ambler class A- and class C-producing Enterobacteriaceae. AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam indicated for the treatment of patients with the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections, used in combination with metronidazole and Complicated Urinary Tract Infections, including Pyelonephritis.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2364670 |
8.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | AVYCAZ Approved UseAVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms: complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole and complicated Urinary Tract Infections (cUTI), including Pyelonephritis. Launch Date2015 |
|||
| Curative | AVYCAZ Approved UseAVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms: complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole and complicated Urinary Tract Infections (cUTI), including Pyelonephritis. Launch Date2015 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.6 mg/L |
0.5 g 3 times / day multiple, intravenous dose: 0.5 g route of administration: Intravenous experiment type: MULTIPLE co-administered: CEFTAZIDIME |
AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
15.2 mg/L |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
38.2 mg × h/L |
0.5 g 3 times / day multiple, intravenous dose: 0.5 g route of administration: Intravenous experiment type: MULTIPLE co-administered: CEFTAZIDIME |
AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
42.1 mg × h/L |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.71 h |
0.5 g 3 times / day multiple, intravenous dose: 0.5 g route of administration: Intravenous experiment type: MULTIPLE co-administered: CEFTAZIDIME |
AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.22 h |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
93% |
0.5 g single, intravenous dose: 0.5 g route of administration: Intravenous experiment type: SINGLE co-administered: Ceftazidime |
[NO STEREO] AVE-1330A FREE ACID|[NO STEREO] AVIBACTAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1000 mg 3 times / day multiple, intravenous Highest studied dose Dose: 1000 mg, 3 times / day Route: intravenous Route: multiple Dose: 1000 mg, 3 times / day Sources: |
healthy, 18–45 years n = 6 Health Status: healthy Age Group: 18–45 years Sex: M Population Size: 6 Sources: |
|
2000 mg single, intravenous Highest studied dose Dose: 2000 mg Route: intravenous Route: single Dose: 2000 mg Sources: |
healthy, 18–45 years n = 6 Health Status: healthy Age Group: 18–45 years Sex: M Population Size: 6 Sources: |
|
500 mg single, oral |
healthy, 28.9 years n = 8 Health Status: healthy Age Group: 28.9 years Sex: M Population Size: 8 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes | ||||
| yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sample Use Guides
AVYCAZ 2.5 grams (ceftazidime 2 grams and avibactam 0.5 grams) for injection administered every 8 hours by intravenous (IV) infusion over 2
hours in patients 18 years of age and older with creatinine clearance (CrCl) greater than 50 mL/min. For treatment of Complicated Intra-abdominal Infections (cIAI), metronidazole should be given concurrently. Recommended duration of treatment: cIAI: 5 to 14 days, Complicated Urinary Tract Infections (cUTI) including pyelonephritis: 7 to 14 days.
Route of Administration:
Intravenous
MICs of ceftazidime/AVE1330A(avibactam) for Enterobacteriaceae were at least eight-fold lower than those of ceftazidime alone. All of the Escherichia coli, Klebsiella pneumoniae, Citrobacter and Proteus mirabilis strains, including ceftazidime-resistant isolates, were inhibited at 4-8 mg/L. Only 2 mg/L were required to inhibit other Proteeae, Enterobacter, Salmonella and Serratia.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:59:16 GMT 2023
by
admin
on
Sat Dec 16 02:59:16 GMT 2023
|
| Record UNII |
9V824P8TAI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C258
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB179984
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
C142942
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL1689063
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
1603833
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | RxNorm | ||
|
85982
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
1383922-24-4
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
SUPERSEDED | |||
|
m2148
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000166051
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
1192491-61-4
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
DB09060
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
DTXSID701027694
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
85984
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
24944097
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
9V824P8TAI
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY | |||
|
9V824P8TAI
Created by
admin on Sat Dec 16 02:59:16 GMT 2023 , Edited by admin on Sat Dec 16 02:59:16 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
